Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.

Autor:	Alikian M; Centre for Haematology, Department of Medicine, Imperial College London Hammersmith Hospital, London UK; Imperial Molecular Pathology, Imperial College Healthcare Trust, Hammersmith Hospital, London, UK., Gale RP; Centre for Haematology, Department of Medicine, Imperial College London Hammersmith Hospital, London UK., Apperley JF; Centre for Haematology, Department of Medicine, Imperial College London Hammersmith Hospital, London UK., Foroni L; Centre for Haematology, Department of Medicine, Imperial College London Hammersmith Hospital, London UK.
Jazyk:	angličtina
Zdroj:	Biomolecular detection and quantification [Biomol Detect Quantif] 2017 Feb 14; Vol. 11, pp. 4-20. Date of Electronic Publication: 2017 Feb 14 (Print Publication: 2017).
DOI:	10.1016/j.bdq.2017.01.001
Abstrakt:	Chronic myeloid leukemia (CML) is the paradigm for targeted cancer therapy. RT-qPCR is the gold standard for monitoring response to tyrosine kinase-inhibitor (TKI) therapy based on the reduction of blood or bone marrow BCR-ABL1 . Some patients with CML and very low or undetectable levels of BCR-ABL1 transcripts can stop TKI-therapy without CML recurrence. However, about 60 percent of patients discontinuing TKI-therapy have rapid leukaemia recurrence. This has increased the need for more sensitive and specific techniques to measure residual CML cells. The clinical challenge is to determine when it is safe to stop TKI-therapy. In this review we describe and critically evaluate the current state of CML clinical management, different technologies used to monitor measurable residual disease (MRD) focus on comparingRT-qPCR and new methods entering clinical practice. We discuss advantages and disadvantages of new methods.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu